This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Centre National De La Recherche Scientifique, Université Paris-Sud 11. Active years: 2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2016
Title: Gaël Le Douaron: Innovator in Neurodegenerative Disease Treatment
Introduction
Gaël Le Douaron is a notable inventor based in Verriere le Buisson, France. He has made significant contributions to the field of medicinal chemistry, particularly in the treatment of neurodegenerative diseases. His innovative work has led to the development of unique compounds that hold promise for medical applications.
Latest Patents
Le Douaron holds a patent for "Aminoquinoxaline derivatives for treatment of neurodegenerative diseases." This invention relates to compounds that can be utilized as medicaments for the treatment or prevention of neurodegenerative diseases. The compounds are characterized by specific chemical structures, which include various substituents that enhance their therapeutic potential. The patent emphasizes the importance of these compounds and their pharmaceutical compositions in addressing critical health challenges.
Career Highlights
Throughout his career, Gaël Le Douaron has worked with prestigious institutions, including the Centre National de la Recherche Scientifique and Université Paris-Sud 11. His research has focused on developing innovative solutions to complex medical problems, particularly in the realm of neurodegenerative conditions. His dedication to advancing scientific knowledge has positioned him as a respected figure in his field.
Collaborations
Le Douaron has collaborated with esteemed colleagues, including Laurent Ferrie and Bruno Figadere. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further enhancing the impact of their research.
Conclusion
Gaël Le Douaron's contributions to the field of neurodegenerative disease treatment through his innovative patents and collaborative efforts highlight his commitment to advancing medical science. His work continues to inspire future research and development in this critical area of healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile